NHS England publishes monthly Hospital and Community Health Services workforce statistics for England. These include staff working for hospital trusts and core organisations, but excludes staff working for other providers such as in primary care, general practice, or social care. This data is drawn from the Electronic Staff Record, the human resources system for the National Health Service. The statistics are available at the following link:<\/p>
<\/p>
https://digital.nhs.uk/data-and-information/publications/statistical/nhs-workforce-statistics<\/a><\/p> <\/p> A large proportion of learning disability nurses work outside NHS trusts, and we do not hold data on where they work. However, the Nursing and Midwifery Council publishes data on the number of nurses on the register across the United Kingdom, which will include nurses employed in other settings, such as education. Data is available in the Fields of Practice sheet in the permanent register data tables, at the following link:<\/p> https://www.nmc.org.uk/about-us/reports-and-accounts/registration-statistics/<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-04-30", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "23731"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-04-30T09:48:48.207Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-25", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Learning Disability: Nurses"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, how many learning disability nurses there (a) are and (b) were in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4048", "label" : {"_value" : "Biography information for Caroline Nokes"}
}
, "tablingMemberConstituency" : {"_value" : "Romsey and Southampton North"}
, "tablingMemberPrinted" : [{"_value" : "Caroline Nokes"}
], "uin" : "23730"}
, {"_about" : "http://data.parliament.uk/resources/1713891", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1713891/answer", "answerText" : {"_value" : " NHS England publishes monthly Hospital and Community Health Services workforce statistics for England. These include staff working for hospital trusts and core organisations, but excludes staff working for other providers such as in primary care, general practice, or social care. This data is drawn from the Electronic Staff Record, the human resources system for the National Health Service. The statistics are available at the following link:<\/p> <\/p> https://digital.nhs.uk/data-and-information/publications/statistical/nhs-workforce-statistics<\/a><\/p> <\/p> A large proportion of learning disability nurses work outside NHS trusts, and we do not hold data on where they work. However, the Nursing and Midwifery Council publishes data on the number of nurses on the register across the United Kingdom, which will include nurses employed in other settings, such as education. Data is available in the Fields of Practice sheet in the permanent register data tables, at the following link:<\/p> https://www.nmc.org.uk/about-us/reports-and-accounts/registration-statistics/<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-04-30", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "23730"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-04-30T09:48:48.253Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-25", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Learning Disability: Nurses"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, how many and what proportion of learning disability nurses are in senior leadership roles.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4048", "label" : {"_value" : "Biography information for Caroline Nokes"}
}
, "tablingMemberConstituency" : {"_value" : "Romsey and Southampton North"}
, "tablingMemberPrinted" : [{"_value" : "Caroline Nokes"}
], "uin" : "23731"}
, {"_about" : "http://data.parliament.uk/resources/1713908", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1713908/answer", "answerText" : {"_value" : " No estimate has been made of expected liver cancer mortality rates by the end of 2025. The care of and treatment for patients with cancer, including liver cancer, is a priority for the Government. Early diagnosis of liver cancer is critical to improving rates of survival. NHS England\u2019s Early Diagnosis of Liver Cancer Programme is contributing to the NHS Long Term Plan\u2019s commitment to diagnose 75% of all cancers at stage one or two by 2028. This programme includes three workstreams: improving liver surveillance programmes; community liver health checks pilots; and primary care pilots. Identifying those at risk and ensuring patients are tested and referred to a surveillance programme, where necessary, will lead to improved patient outcomes.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-04-30", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-04-30T09:55:44.56Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-25", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Liver Cancer: Mortality Rates"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether she has made an estimate of expected liver cancer mortality rates by the end of 2025.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1409", "label" : {"_value" : "Biography information for Mr Gregory Campbell"}
}
, "tablingMemberConstituency" : {"_value" : "East Londonderry"}
, "tablingMemberPrinted" : [{"_value" : "Mr Gregory Campbell"}
], "uin" : "23699"}
, {"_about" : "http://data.parliament.uk/resources/1713932", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1713932/answer", "answerText" : {"_value" : " Since publication of the Future of Clinical Research Delivery, we have developed early versions of several products as part of the Find, Recruit and Follow-up Service, to deliver secure data enabled study feasibility and recruitment within established governance and legal requirements, across England and other parts of the United Kingdom.<\/p> <\/p> These products include: NHS England\u2019s DigiTrials self-service feasibility tool, which identifies suitable locations for studies by establishing where the largest groupings of eligible people are based; NHS England\u2019s DigiTrials recruitment service, which is currently in its second phase of pilots and will enable the National Health Service to more easily approach patients about research relevant to them; the Medicines and Healthcare products Regulatory Agency\u2019s Clinical Research Practice Datalink, which allows participating general practices to identify potentially eligible patients for relevant studies more easily; and the Be Part of Research registry, which allows people to proactively register their interest in participating in research.<\/p> <\/p> These tools have been developed to increase the efficiency and effectiveness of the clinical research process, and also improve our ability to widen access to research opportunities, increase the resilience and sustainability of the healthcare system, and reduce the burden on the NHS workforce.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-04-30", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-04-30T10:48:51.65Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-25", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Clinical Trials"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the paper entitled The Future of Clinical Research Delivery: 2022 to 2025 implementation plan, published on 30 June 2022, what progress has been made on the Find, Recruit and Follow-up service for clinical trials.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4124", "label" : {"_value" : "Biography information for Chi Onwurah"}
}
, "tablingMemberConstituency" : {"_value" : "Newcastle upon Tyne Central"}
, "tablingMemberPrinted" : [{"_value" : "Chi Onwurah"}
], "uin" : "23739"}
, {"_about" : "http://data.parliament.uk/resources/1713933", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1713933/answer", "answerText" : {"_value" : " The National Contract Value Review (NCVR) process applies to commercial clinical studies. NHS England is working in partnership with the devolved administrations, the National Institute for Health and Care Research, and other partners, to pilot the use of the NCVR process for phase I and IIa of commercial clinical trials. The ambition is to make the use of NCVR for phase I and IIa of commercial clinical trials mainstream from October 2024.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-04-30", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-04-30T09:57:50.757Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-25", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Clinical Trials: Contracts"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the policy paper entitled Full government response to the Lord O'Shaughnessy review into commercial clinical trials, last updated on 8 December 2023, what her Department's planned timetable is for expanding the national contract value review programme to phase 1 and 2a clinical trials.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4124", "label" : {"_value" : "Biography information for Chi Onwurah"}
}
, "tablingMemberConstituency" : {"_value" : "Newcastle upon Tyne Central"}
, "tablingMemberPrinted" : [{"_value" : "Chi Onwurah"}
], "uin" : "23740"}
, {"_about" : "http://data.parliament.uk/resources/1713936", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1713936/answer", "answerText" : {"_value" : " The Medicines and Healthcare products Regulatory Agency (MHRA) performs the functions of my Rt hon. Friend, the Secretary of State for Health and Social Care, under United Kingdom legislation, relating to the regulation of medicines, medical devices, and blood products for transfusion. The MHRA also performs the functions of my Rt hon. Friend, the Secretary of State for Health and Social Care in relation to the standardisation and control of biological medicines including vaccines, blood products, and other substances which cannot be characterised chemically, and which require special testing measures to ensure their safety and efficacy.<\/p> My Rt hon. Friend, the Secretary of State for Health and Social Care has ministerial responsibility for, and oversight of, the MHRA\u2019s delivery and performance. The MHRA seeks ministerial agreement for policy and legislative framework changes. Ministers are not involved in individual decisions made by the MHRA. The MHRA is held to account through regular established mechanisms including quarterly and annual accountability reviews. A framework agreement between the Department and the MHRA also sets out the governance structure within which both parties operate, with further information available at the following link:<\/p> https://www.gov.uk/government/publications/dh-and-mhra-framework-agreement/framework-agreement-between-dhsc-and-the-medicines-and-healthcare-products-regulatory-agency<\/a><\/p> The MHRA also publishes performance figures each month, as well as its annual report and accounts, and the minutes of the latest Annual Accountability Review with the MHRA is available at the following link:<\/p> https://www.gov.uk/government/publications/annual-accountability-review-mhra/annual-accountability-review-minutes-2022-to-2023-3-july-2023<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-04-30", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "23761"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-04-30T09:52:08.65Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-25", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Medicines and Healthcare Products Regulatory Agency: Accountability"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, how the Medicines and Healthcare products Regulatory Agency is held accountable for its decisions.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4471", "label" : {"_value" : "Biography information for Rachael Maskell"}
}
, "tablingMemberConstituency" : {"_value" : "York Central"}
, "tablingMemberPrinted" : [{"_value" : "Rachael Maskell"}
], "uin" : "23760"}
, {"_about" : "http://data.parliament.uk/resources/1713937", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1713937/answer", "answerText" : {"_value" : " The Medicines and Healthcare products Regulatory Agency (MHRA) performs the functions of my Rt hon. Friend, the Secretary of State for Health and Social Care, under United Kingdom legislation, relating to the regulation of medicines, medical devices, and blood products for transfusion. The MHRA also performs the functions of my Rt hon. Friend, the Secretary of State for Health and Social Care in relation to the standardisation and control of biological medicines including vaccines, blood products, and other substances which cannot be characterised chemically, and which require special testing measures to ensure their safety and efficacy.<\/p> My Rt hon. Friend, the Secretary of State for Health and Social Care has ministerial responsibility for, and oversight of, the MHRA\u2019s delivery and performance. The MHRA seeks ministerial agreement for policy and legislative framework changes. Ministers are not involved in individual decisions made by the MHRA. The MHRA is held to account through regular established mechanisms including quarterly and annual accountability reviews. A framework agreement between the Department and the MHRA also sets out the governance structure within which both parties operate, with further information available at the following link:<\/p> https://www.gov.uk/government/publications/dh-and-mhra-framework-agreement/framework-agreement-between-dhsc-and-the-medicines-and-healthcare-products-regulatory-agency<\/a><\/p> The MHRA also publishes performance figures each month, as well as its annual report and accounts, and the minutes of the latest Annual Accountability Review with the MHRA is available at the following link:<\/p> https://www.gov.uk/government/publications/annual-accountability-review-mhra/annual-accountability-review-minutes-2022-to-2023-3-july-2023<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-04-30", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "23760"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-04-30T09:52:08.697Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-25", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Medicines and Healthcare Products Regulatory Agency"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps is she taking to review the decisions of the Medicines and Healthcare products Regulatory Agency.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4471", "label" : {"_value" : "Biography information for Rachael Maskell"}
}
, "tablingMemberConstituency" : {"_value" : "York Central"}
, "tablingMemberPrinted" : [{"_value" : "Rachael Maskell"}
], "uin" : "23761"}
, {"_about" : "http://data.parliament.uk/resources/1713406", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1713406/answer", "answerText" : {"_value" : " The implantation of a duodenal\u2013jejunal bypass liner, also known as an endo barrier, for managing type 2 diabetes, is not recommended by the NICE, and therefore not available on the National Health Service. Current evidence on the safety and efficacy of the device for managing type 2 diabetes is limited in quality and quantity. For this reason, the NICE recommends that the procedure should only be done as part of a research study. Further information on the NICE guidelines is available at the following link:<\/p> https://www.nice.org.uk/guidance/ipg518/chapter/1-Recommendations<\/a><\/p> The NICE may update the guidance, upon publication of further evidence. The NICE recommends that people with type 2 diabetes receive eight care processes at least annually, to support them to achieve three treatment targets to prevent diabetes related complications. The care processes include checks on blood glucose and body mass index, to support weight management. Delivery of all eight care processes is associated with reduced emergency admissions, amputations, and retinopathy. NHS England commissions two national lifestyle services to support adults with type 2 diabetes to manage their weight and improve their health and wellbeing. These are the NHS Digital Weight Management Programme and the NHS Type 2 Diabetes Path to Remission Programme. The NICE guidance for the care and management for adults with type 2 diabetes is available at the following link:<\/p>